Nathan Lee

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models

Helen Y. Zou, Luc Friboulet, David P. Kodack et al. · Cancer Cell · 2015 · 463 citations · Full text

Medicine, Oncology, Pharmacology +14

GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer

Paul D.P. Pharoah, Ya-Yu Tsai, Susan J. Ramus et al. · Nature Genetics · 2013 · 361 citations · Full text

Life Sciences, Genetics, Oncology +14

A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro

Janet Myungjin Lee, Paulette Mhawech‐Fauceglia, Nathan Lee et al. · Laboratory Investigation · 2013 · 303 citations

Medicine, Cell Biology, Oncology +14

Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor

Kevin D. Freeman‐Cook, Robert L. Hoffman, Nichol Miller et al. · Cancer Cell · 2021 · 186 citations

Life Sciences, Cancer Biology, Oncology +14

Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31

Jennifer Permuth‐Wey, Kate Lawrenson, Howard C. Shen et al. · Nature Communications · 2013 · 110 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17